Loomis, Sayles & Company’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-548
| Closed | -$36K | – | 747 |
|
|
2024
Q3 | $36K | Buy |
548
+10
| +2% | +$657 | ﹤0.01% | 659 |
|
|
2024
Q2 | $50K | Buy |
538
+11
| +2% | +$1.02K | ﹤0.01% | 632 |
|
|
2024
Q1 | $50K | Sell |
527
-6
| -1% | -$569 | ﹤0.01% | 618 |
|
|
2023
Q4 | $41K | Sell |
533
-415
| -44% | -$31.9K | ﹤0.01% | 623 |
|
|
2023
Q3 | $66K | Buy |
948
+93
| +11% | +$6.48K | ﹤0.01% | 568 |
|
|
2023
Q2 | $81K | Buy |
855
+408
| +91% | +$38.7K | ﹤0.01% | 551 |
|
|
2023
Q1 | $37K | Sell |
447
-157
| -26% | -$13K | ﹤0.01% | 666 |
|
|
2022
Q4 | $45K | Buy |
604
+448
| +287% | +$33.4K | ﹤0.01% | 621 |
|
|
2022
Q3 | $13K | Sell |
156
-879
| -85% | -$73.3K | ﹤0.01% | 649 |
|
|
2022
Q2 | $98K | Sell |
1,035
-223
| -18% | -$21.1K | ﹤0.01% | 544 |
|
|
2022
Q1 | $148K | Buy |
1,258
+23
| +2% | +$2.71K | ﹤0.01% | 567 |
|
|
2021
Q4 | $160K | Hold |
1,235
| – | – | ﹤0.01% | 575 |
|
|
2021
Q3 | $140K | Hold |
1,235
| – | – | ﹤0.01% | 552 |
|
|
2021
Q2 | $128K | Sell |
1,235
-16
| -1% | -$1.66K | ﹤0.01% | 553 |
|
|
2021
Q1 | $105K | Hold |
1,251
| – | – | ﹤0.01% | 553 |
|
|
2020
Q4 | $114K | Hold |
1,251
| – | – | ﹤0.01% | 526 |
|
|
2020
Q3 | $100K | Hold |
1,251
| – | – | ﹤0.01% | 537 |
|
|
2020
Q2 | $86K | Buy |
1,251
+21
| +2% | +$1.44K | ﹤0.01% | 531 |
|
|
2020
Q1 | $77K | Hold |
1,230
| – | – | ﹤0.01% | 542 |
|
|
2019
Q4 | $96K | Buy |
+1,230
| New | +$96K | ﹤0.01% | 589 |
|